CorMedix resubmits DefenCath NDA to FDA for hemodialysis catheter infection prevention

CorMedix Inc.

NDA for DefenCath resubmitted to FDA as of May 15, 2023; agency acknowledged receipt for processing.
CEO Joe Todisco said resubmission follows prior earnings call; company aims for potential approval in 2023.
DefenCath is designed to reduce bloodstream infections in hemodialysis patients using central venous catheters.
Resubmission addresses prior FDA feedback; no specific timeline for review decision provided.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.